

HEMOSENSE INC  
Form 8-K  
February 21, 2007

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**  
**the Securities Exchange Act of 1934**

February 20, 2007

Date of Report (date of earliest event reported)

---

**HEMOSENSE, INC.**

(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**001-32541**  
(Commission File Number)

**77-0452938**  
(I.R.S. Employer

Identification Number)

**651 River Oaks Parkway**

**San Jose, California 95134**

(Address of principal executive offices)

**(408) 719-1393**

(Registrant's telephone number, including area code)

Edgar Filing: HEMOSENSE INC - Form 8-K

N/A

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events**

HemoSense, Inc. (the Company) hereby confirms that Edward F. Brennan, a member of the Company's board of directors, is deemed by the Company to be an independent director pursuant the rules established by the American Stock Exchange, notwithstanding a sentence inadvertently to the contrary in the Company's proxy statement for its 2007 Annual Meeting of Stockholders.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**HEMOSENSE, INC.**

Date: February 20, 2007

By: /s/ Gordon Sangster  
Gordon Sangster  
Vice President, Finance and Chief Financial Officer